Manos Perros, Ph.D.

Dr. Manos Perros, Ph.D., is a pharmaceutical and biotech executive with over 25 years of experience in life sciences R&D. Dr. Perros began his career as a chemist and conducted his Ph.D. work in Belgium, France, and Germany before joining the Biophysics Department at Yale University in 1993.

Between 2015 and 2022, Manos was the founding Chief Executive Officer of Entasis Therapeutics, where he played a pivotal role in establishing the company as a prominent player in the industry and the acquisition of the company by Innoviva in 2022. His work at Entasis culminated in the FDA approval of Xacduro, the first targeted treatment for Acinetobacter baumannii pneumonia, in 2023 and Nuzolvence, a first-in-class oral treatment for gonorrhea in 2025 . Before founding Entasis, Dr. Perros held the position of Vice President and Head of AstraZeneca’s Infection Research and Early Development and Site Head for AstraZeneca’s Boston R&D research center. Before AstraZeneca, Dr. Perros served as Director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as Vice-President and Chief Scientific Officer, Antivirals, at Pfizer, where he led the R&D program which culminated in the approval of Selzentry, a first-in-class treatment for HIV. While at Pfizer, he also directed research in a variety of therapeutic areas including Obesity, Pain, and Urology.

Throughout his illustrious career, Dr. Perros has successfully led numerous organizations through various stages of growth and development, earning him a reputation as a visionary leader in the industry. Manos Perros has also made substantial contributions to the field of anti-infectives, and he is widely recognized and published as a distinguished scientist, having led research projects against HIV, Hepatitis C, influenza, as well as bacterial and fungal pathogens.

Dr. Perros is currently Chairman of the Board at Aurobac Therapeutics, Executive Chairman of the Board at Venatorx Pharmaceuticals and Chairman of the Scientific Advisory Board of the Global Health Drug Discovery Institute (Beijing).